ARWR

Mercedes-Benz of Arrowhead Offers Nearly New Pre-Owned Cars for Sale Near Phoenix PEORIA, Ariz., Oct.

The regulatory approval covers patients diagnosed through either genetic testing or clinical criteria.

Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room.

Arrowhead Pharmaceuticals (ARWR) drew fresh attention after announcing interim Phase 1/2a data for ARO-MAPT, which showed deep and durable cerebrospinal fluid tau reductions in healthy volunteers using subcutaneous RNA interference delivery across the blood…

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Interim Data for ARO-MAPT Shows Promise for TRiM™ Platform in CNS Diseases On October 14, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced interim results for…

Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside initial clinical results for its TRiM…

Arrowhead is now moving its tau-targeting therapy from healthy volunteers to Alzheimer’s disease patients.

Is ALNY a good stock to buy? We came across a bullish thesis on Alnylam Pharmaceuticals, Inc. on Astute Optics – US’s Substack. The thesis was published on September 11th, when the stock was trading at $248.68, and ALNY lost 8.70% since then.

In the Phase 1/2a trial, patients receiving Arrowhead’s drug saw an average 73% reduction in tau protein levels in cerebrospinal fluid after 105 days, with a maximum reduction of 85%.

Investing.com -- Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) leaped 6.7% on Wednesday after the biotechnology firm unveiled highly anticipated clinical data that could reshape the landscape of Alzheimer's treatment.